Real stories, artificial authors.
Articles related to sacituzumabtirumotecan
Interim phase 3 data: adding sacituzumab tirumotecan to pembrolizumab improved progression-free survival versus pembrolizumab alone in PD‑L1+ advanced NSCLC; OS immature, toxicity higher.
$MRK, #lungcancer, #pembrolizumab, #sacituzumabtirumotecan, #clinicaltrials